Compare ALUR & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | MRKR |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 16.6M |
| IPO Year | N/A | N/A |
| Metric | ALUR | MRKR |
|---|---|---|
| Price | $1.36 | $1.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.25 | ★ $10.17 |
| AVG Volume (30 Days) | 111.0K | ★ 345.5K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.81 |
| 52 Week High | $16.81 | $5.95 |
| Indicator | ALUR | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 53.86 |
| Support Level | $1.46 | $1.25 |
| Resistance Level | $1.71 | $1.48 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.16 | 42.65 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.